AI assistant
Sending…
Jazz Pharmaceuticals plc — Director's Dealing 2025
Jan 23, 2025
30751_dirs_2025-01-22_8f5fe67d-25b3-4dde-b5fd-86f13092a845.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2025-01-17
Reporting Person: GALA RENEE D (President & COO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-01-17 | Ordinary Shares | A | 7741 | $0.0 | Acquired | 63233 | Direct |
| 2025-01-17 | Ordinary Shares | F | 3300 | $122.62 | Disposed | 59933 | Direct |
Footnotes
F1: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2022. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2025, which represents the date on which the level of performance attained was certified.
F2: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations.
More from Jazz Pharmaceuticals plc
Board/Management Information
2026
May 29
Annual Report
2026
Apr 24
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2